Litcius/Paper detail

Let-7a/cMyc/CCAT1/miR-17–5p Circuit Re-sensitizes Atezolizumab Resistance in Triple Negative Breast Cancer through Modulating PD-L1

Noha A. Selem, Heba Nafae, Tamer Manie, R.A. Youness, Mohamed Z. Gad

2023Pathology - Research and Practice37 citationsDOI

Topics & Concepts

AtezolizumabTriple-negative breast cancerCancer researchEctopic expressionGene knockdownBreast cancermicroRNACancerOncologyMedicineBiologyInternal medicineCell cultureImmunotherapyNivolumabGeneticsGeneBiochemistryCancer Immunotherapy and BiomarkersMicroRNA in disease regulationFerroptosis and cancer prognosis
Let-7a/cMyc/CCAT1/miR-17–5p Circuit Re-sensitizes Atezolizumab Resistance in Triple Negative Breast Cancer through Modulating PD-L1 | Litcius